Printer Friendly
The Free Library
14,588,739 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

ZOLL Launches E Series Defibrillator Designed for EMS Professionals.


CHELMSFORD, Mass. -- ZOLL Medical Corporation (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: ZOLL), a manufacturer of resuscitation resuscitation /re·sus·ci·ta·tion/ (-sus?i-ta´shun) restoration to life of one apparently dead.

cardiopulmonary resuscitation
 devices and software solutions, announced today the launch of the E Series(TM), ZOLL's newest defibrillator defibrillator, device that delivers an electrical shock to the heart in order to stop certain forms of rapid heart rhythm disturbances (arrhythmias). The shock changes a fibrillation to an organized rhythm or changes a very rapid and ineffective cardiac rhythm to a  designed to meet the specific demands and extreme conditions of the EMS environment (temperature, moisture, and portability). ZOLL is accepting orders for the E Series and plans to begin shipments by the end of September 2005.

The first EMS agency to purchase the E Series is Peoria, Ill.-based Advanced Medical Transport (AMT See vPro. ), which operates the largest ambulance fleet in Central Illinois. According to AMT's Executive Director, Andrew Rand, "The innovative design and feature set of the E Series make it apparent that ZOLL has listened to professional rescuers and built a top-notch defibrillator designed exclusively for the world of EMS. We purchased the E Series because of ZOLL's clear understanding of what it takes to develop the best life-saving tools for caregivers and their patients."

The E Series is the only defibrillator available today that:

--Features a suitcase-style design with an innovative, protective roll cage, allowing EMS customers to carry or store the device more easily;

--Exceeds all other defibrillators in terms of overall ruggedness and durability;

--Provides an EasyRead Tri-Mode Display(TM) for use in pitch dark or direct sunlight, providing superior readability and complete views of critical patient information from virtually any angle;

--Is equipped with a built-in GPS clock, allowing customers to automatically synchronize all of their dispatch, defibrillator, and intervention call times, improving overall data accuracy;

--Offers a Rapid Cable Deployment System(TM) that helps manage all the parameter cables, allowing for faster deployment and avoiding the "spaghetti in the bag" that can be associated with other defibrillators;

--Is compatible with ZOLL's sealed lead acid 4410 Smart Battery(TM) as well rechargeable lithium ion, allowing the E Series to function with new and existing battery technologies; and

--Integrates optional Bluetooth(R) functionality to provide data transmission capability to a variety of destinations.

In addition, the E Series is RescueNet(TM) Ready and can easily transfer patient and clinical data to ZOLL's range of RescueNet Field Data collection options. RescueNet is the only suite of fully integrated EMS software applications that combines patient and medical device information, and streamlines operations by managing data from the emergency call to patient billing.

The E Series uses ZOLL's proprietary Rectilinear rec·ti·lin·e·ar  
adj.
Moving in, consisting of, bounded by, or characterized by a straight line or lines: following a rectilinear path; rectilinear patterns in wallpaper.
 Biphasic bi·pha·sic  
adj.
Having two distinct phases: a biphasic waveform; a biphasic response to a stimulus. 
(TM) Waveform (RBW RBW Resolution Bandwidth
RBW Reverse Band Working
RBW Range Bin Width
RBW Right Brain Works
RBW Ruby Web File
). The ZOLL RBW is the only biphasic waveform cleared by the FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 to claim superiority to monophasic waveforms for the conversion of ventricular fibrillation ventricular fibrillation

Uncoordinated contraction of the muscle fibres of the heart's ventricles (see arrhythmia). Causes include heart attack, electric shock, anoxia, abnormally high potassium or low calcium in the blood, and digitalis or epinephrine poisoning (
 in high impedance patients. ZOLL is the only company to receive this FDA clearance to make such superiority claims since the development of defibrillation Defibrillation Definition

Defibrillation is a process in which an electronic device sends an electric shock to the heart to stop an extremely rapid, irregular heartbeat, and restore the normal heart rhythm.
 in the 1950s. Only the ZOLL RBW has demonstrated statistical clinical superiority to monophasic waveforms in peer-reviewed controlled trials, with data from more than 11,500 patients.

"The E Series builds on the success of the well-established M Series(TM) line of defibrillators, while offering a number of industry firsts in the areas of design, usability, documentation, and data management," said Richard A. Packer, President and Chief Executive Officer of ZOLL. "We are encouraged by the positive early reaction to the product from the EMS marketplace."

Mr. Packer continued, "While we expect that this introduction will help us continue to gain traction in the EMS marketplace, revenue from the E Series will ramp up Ramp Up

To increase a company's operations in anticipation of increased demand.

Notes:
A company might 'ramp up' operations if they just signed a contract creating substantially more demand for their product.
See also: Demand, Economies of Scale
 over time and will have a moderate effect on the fourth quarter. In addition, we expect sales of the E Series to help drive adoption of other products, such as the ZOLL AutoPulse,(TM) as more customers understand how ZOLL's products work together to advance the practice of resuscitation, and help rescuers save lives that would otherwise be lost."

About ZOLL Medical Corporation

ZOLL Medical Corporation (NASDAQ: ZOLL) is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation fluid resuscitation Critical care medicine The infusion of isotonic IV fluids to a hypotensive Pt with trauma; aggressive FR may disrupt thrombi, ↑ bleeding, and ↓ survival , ZOLL provides a comprehensive set of technologies that can help clinicians, EMS professionals, and lay rescuers resuscitate re·sus·ci·tate
v.
To restore consciousness, vigor, or life to.
 sudden cardiac arrest cardiac arrest
n.
Abbr. CA A sudden cessation of cardiac function, resulting in loss of effective circulation.


Cardiac arrest
A condition in which the heart stops functioning.
 or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical data.

ZOLL has operations in the United States, Canada, the United Kingdom, Germany, France, The Netherlands, Australia, and Austria. With direct operations, international offices, and business partners in all of the world's major markets, ZOLL markets and sells its products in more than 140 countries.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, expectations concerning future product revenues and financial results and other statements contained in this press release regarding matters that are not historical facts, are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled "Risk Factors" in the Company's Quarterly Report on Form 10Q filed with the SEC on May 13, 2005, including the future performance of the direct sales operations, as well as uncertainties regarding the market acceptance and profitability of the Company's products.

Copyright (C) 2005 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AutoPulse, E Series, EasyRead Tri-Mode Display, M Series, Rapid Cable Deployment System, Rectilinear Biphasic, RescueNet, and Smart Battery are trademarks of ZOLL Medical Corporation. ZOLL is a registered trademark of ZOLL Medical Corporation. All trademarks are property of their respective owners.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 26, 2005
Words:934
Previous Article:Navigant International (FLYR.PK) Reports Second Quarter Revenue of $125.7 Million.
Next Article:American Shared Hospital Services Reports 15% Revenue Growth and 8% Increase in Operating Income for the Second Quarter of 2005.
Topics:



Related Articles
Contributing sponsors.
Duracell and Zoll Medical Corporation Award Automated External Defibrillators to Winning U.S. Schools; Fifty-One Contest Winners Nationwide Receive...
ZOLL Medical Corporation Announces Third Quarter Results; Revenue Declines in Spite of Higher Order Growth.
First Major ZOLL AutoPulse Purchase in the United Kingdom; 20 AutoPulse Devices Part of a GBP 1 Million Order from Essex Ambulance Service NHS Trust.
ZOLL Receives FDA Marketing Clearance for New Hospital Device.
Mass.-Based Armstrong Ambulance Service Upgrades to ZOLL Resuscitation Equipment.
ZOLL Launches First and Only "Code-Ready" Defibrillator for Hospitals: R Series.
East of England Ambulance Service NHS Trust Purchases ZOLL's State-of-the-Art Resuscitation Technology.
ZOLL Receives Marketing Clearance for R Series "Code-Ready" Defibrillator in Canada.
ZOLL Receives Marketing Clearance for E Series with Real CPR Help Technology.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles